NASDAQ:CNSP - Nasdaq - US18978H4092 - Common Stock - Currency: USD
6.99
-0.46 (-6.17%)
The current stock price of CNSP is 6.99 USD. In the past month the price decreased by -35.81%. In the past year, price decreased by -93.47%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 46.57 | 607.37B | ||
JNJ | JOHNSON & JOHNSON | 17.15 | 413.10B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 16.8 | 231.20B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.1 | 224.40B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 12.41 | 216.66B | ||
MRK | MERCK & CO. INC. | 10.44 | 201.81B | ||
PFE | PFIZER INC | 7.15 | 137.76B | ||
SNY | SANOFI-ADR | 10.78 | 115.68B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 6.74 | 92.31B | ||
GSK | GSK PLC-SPON ADR | 8.39 | 75.83B | ||
ZTS | ZOETIS INC | 23.83 | 66.00B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 47.87 | 45.35B |
CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. The company is headquartered in Houston, Texas and currently employs 4 full-time employees. The company went IPO on 2019-11-08. The firm's drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier. Berubicin is the subject of the Company's late-stage, fully-enrolled, global clinical trial for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The firm's drug candidate, TPI 287, is an abeotaxane which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. TPI 287 has shown the potential to cross the blood-brain barrier and treat central nervous system (CNS) tumors.
CNS PHARMACEUTICALS INC
2100 West Loop S Ste 900
Houston TEXAS 77027 US
CEO: John Climaco
Employees: 5
Phone: 18009469185
The current stock price of CNSP is 6.99 USD. The price decreased by -6.17% in the last trading session.
The exchange symbol of CNS PHARMACEUTICALS INC is CNSP and it is listed on the Nasdaq exchange.
CNSP stock is listed on the Nasdaq exchange.
CNS PHARMACEUTICALS INC (CNSP) has a market capitalization of 3.22M USD. This makes CNSP a Nano Cap stock.
CNS PHARMACEUTICALS INC (CNSP) currently has 5 employees.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CNSP does not pay a dividend.
CNS PHARMACEUTICALS INC (CNSP) will report earnings on 2025-08-12.
CNS PHARMACEUTICALS INC (CNSP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-358.5).
ChartMill assigns a fundamental rating of 2 / 10 to CNSP. CNSP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months CNSP reported a non-GAAP Earnings per Share(EPS) of -358.5. The EPS increased by 96% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -113.56% | ||
ROE | -142.33% | ||
Debt/Equity | 0.02 |
ChartMill assigns a Buy % Consensus number of 80% to CNSP. The Buy consensus is the average rating of analysts ratings from 8 analysts.